nodes	percent_of_prediction	percent_of_DWPC	metapath
Podofilox—Etoposide—urinary bladder cancer	0.461	1	CrCtD
Podofilox—Teniposide—Etoposide—urinary bladder cancer	0.262	1	CrCrCtD
Podofilox—TOP2A—Valrubicin—urinary bladder cancer	0.158	0.714	CbGbCtD
Podofilox—TOP2A—Epirubicin—urinary bladder cancer	0.0239	0.108	CbGbCtD
Podofilox—TOP2A—Etoposide—urinary bladder cancer	0.0186	0.0843	CbGbCtD
Podofilox—TOP2A—Doxorubicin—urinary bladder cancer	0.0127	0.0575	CbGbCtD
Podofilox—CYP3A4—Thiotepa—urinary bladder cancer	0.0055	0.0249	CbGbCtD
Podofilox—CYP3A4—Etoposide—urinary bladder cancer	0.00149	0.00675	CbGbCtD
Podofilox—CYP2C19—urine—urinary bladder cancer	0.00126	0.0769	CbGeAlD
Podofilox—TUBA4A—prostate gland—urinary bladder cancer	0.00104	0.0635	CbGeAlD
Podofilox—CYP3A4—Doxorubicin—urinary bladder cancer	0.00102	0.00461	CbGbCtD
Podofilox—NR3C1—urine—urinary bladder cancer	0.000986	0.0601	CbGeAlD
Podofilox—TUBA4A—seminal vesicle—urinary bladder cancer	0.000881	0.0537	CbGeAlD
Podofilox—TOP2A—prostate gland—urinary bladder cancer	0.000771	0.047	CbGeAlD
Podofilox—Etoposide—GSTT1—urinary bladder cancer	0.000766	0.49	CrCbGaD
Podofilox—TUBA4A—epithelium—urinary bladder cancer	0.000766	0.0467	CbGeAlD
Podofilox—TUBB—prostate gland—urinary bladder cancer	0.000764	0.0466	CbGeAlD
Podofilox—CYP3A4—urine—urinary bladder cancer	0.000746	0.0455	CbGeAlD
Podofilox—TUBA4A—smooth muscle tissue—urinary bladder cancer	0.000738	0.045	CbGeAlD
Podofilox—Scab—Fluorouracil—urinary bladder cancer	0.000711	0.0343	CcSEcCtD
Podofilox—TUBA4A—renal system—urinary bladder cancer	0.00071	0.0433	CbGeAlD
Podofilox—TUBA4A—urethra—urinary bladder cancer	0.000698	0.0425	CbGeAlD
Podofilox—Stinging—Mitomycin—urinary bladder cancer	0.000671	0.0324	CcSEcCtD
Podofilox—TUBB—seminal vesicle—urinary bladder cancer	0.000646	0.0394	CbGeAlD
Podofilox—Etoposide—GSTP1—urinary bladder cancer	0.000606	0.387	CrCbGaD
Podofilox—Ulcer—Mitomycin—urinary bladder cancer	0.000575	0.0278	CcSEcCtD
Podofilox—TUBA4A—female reproductive system—urinary bladder cancer	0.000569	0.0347	CbGeAlD
Podofilox—TUBB—smooth muscle tissue—urinary bladder cancer	0.000541	0.033	CbGeAlD
Podofilox—TUBA4A—vagina—urinary bladder cancer	0.000514	0.0314	CbGeAlD
Podofilox—Application site pain—Fluorouracil—urinary bladder cancer	0.000514	0.0248	CcSEcCtD
Podofilox—TUBB—urethra—urinary bladder cancer	0.000511	0.0312	CbGeAlD
Podofilox—Haematuria—Valrubicin—urinary bladder cancer	0.000421	0.0203	CcSEcCtD
Podofilox—TOP2A—vagina—urinary bladder cancer	0.000381	0.0232	CbGeAlD
Podofilox—TUBB—vagina—urinary bladder cancer	0.000377	0.023	CbGeAlD
Podofilox—NR3C1—prostate gland—urinary bladder cancer	0.000354	0.0216	CbGeAlD
Podofilox—TUBA4A—lymph node—urinary bladder cancer	0.000333	0.0203	CbGeAlD
Podofilox—Blister—Fluorouracil—urinary bladder cancer	0.000314	0.0151	CcSEcCtD
Podofilox—Skin discolouration—Thiotepa—urinary bladder cancer	0.000303	0.0146	CcSEcCtD
Podofilox—NR3C1—seminal vesicle—urinary bladder cancer	0.000299	0.0183	CbGeAlD
Podofilox—Tingling sensation—Fluorouracil—urinary bladder cancer	0.000281	0.0136	CcSEcCtD
Podofilox—Stinging—Fluorouracil—urinary bladder cancer	0.000279	0.0135	CcSEcCtD
Podofilox—Tenderness—Gemcitabine—urinary bladder cancer	0.000264	0.0127	CcSEcCtD
Podofilox—Skin exfoliation—Thiotepa—urinary bladder cancer	0.000261	0.0126	CcSEcCtD
Podofilox—NR3C1—epithelium—urinary bladder cancer	0.00026	0.0159	CbGeAlD
Podofilox—Tenderness—Fluorouracil—urinary bladder cancer	0.000259	0.0125	CcSEcCtD
Podofilox—NR3C1—smooth muscle tissue—urinary bladder cancer	0.000251	0.0153	CbGeAlD
Podofilox—TOP2A—lymph node—urinary bladder cancer	0.000246	0.015	CbGeAlD
Podofilox—Tenderness—Cisplatin—urinary bladder cancer	0.000246	0.0119	CcSEcCtD
Podofilox—Tingling sensation—Etoposide—urinary bladder cancer	0.000244	0.0118	CcSEcCtD
Podofilox—TUBB—lymph node—urinary bladder cancer	0.000244	0.0149	CbGeAlD
Podofilox—Ulcer—Gemcitabine—urinary bladder cancer	0.000243	0.0117	CcSEcCtD
Podofilox—NR3C1—renal system—urinary bladder cancer	0.000241	0.0147	CbGeAlD
Podofilox—Ulcer—Fluorouracil—urinary bladder cancer	0.000239	0.0115	CcSEcCtD
Podofilox—Erythema—Mitomycin—urinary bladder cancer	0.000238	0.0115	CcSEcCtD
Podofilox—NR3C1—urethra—urinary bladder cancer	0.000237	0.0144	CbGeAlD
Podofilox—Inflammation—Fluorouracil—urinary bladder cancer	0.000233	0.0113	CcSEcCtD
Podofilox—Ulcer—Cisplatin—urinary bladder cancer	0.000227	0.0109	CcSEcCtD
Podofilox—CYP2C19—vagina—urinary bladder cancer	0.000224	0.0136	CbGeAlD
Podofilox—Pain—Carboplatin—urinary bladder cancer	0.000223	0.0108	CcSEcCtD
Podofilox—Skin exfoliation—Gemcitabine—urinary bladder cancer	0.00022	0.0106	CcSEcCtD
Podofilox—Skin discolouration—Etoposide—urinary bladder cancer	0.000217	0.0105	CcSEcCtD
Podofilox—Ulcer—Etoposide—urinary bladder cancer	0.000208	0.01	CcSEcCtD
Podofilox—Skin exfoliation—Cisplatin—urinary bladder cancer	0.000205	0.00988	CcSEcCtD
Podofilox—Inflammation—Etoposide—urinary bladder cancer	0.000203	0.00978	CcSEcCtD
Podofilox—Pruritus—Valrubicin—urinary bladder cancer	0.000199	0.00962	CcSEcCtD
Podofilox—Oedema—Mitomycin—urinary bladder cancer	0.000194	0.00937	CcSEcCtD
Podofilox—NR3C1—female reproductive system—urinary bladder cancer	0.000193	0.0118	CbGeAlD
Podofilox—Etoposide—PTGS2—urinary bladder cancer	0.000192	0.123	CrCbGaD
Podofilox—Skin exfoliation—Etoposide—urinary bladder cancer	0.000188	0.00905	CcSEcCtD
Podofilox—Dizziness—Valrubicin—urinary bladder cancer	0.000186	0.00899	CcSEcCtD
Podofilox—Swelling—Fluorouracil—urinary bladder cancer	0.000186	0.00898	CcSEcCtD
Podofilox—CYP3A4—renal system—urinary bladder cancer	0.000182	0.0111	CbGeAlD
Podofilox—Vomiting—Valrubicin—urinary bladder cancer	0.000179	0.00864	CcSEcCtD
Podofilox—Rash—Valrubicin—urinary bladder cancer	0.000178	0.00857	CcSEcCtD
Podofilox—Dermatitis—Valrubicin—urinary bladder cancer	0.000177	0.00856	CcSEcCtD
Podofilox—Headache—Valrubicin—urinary bladder cancer	0.000176	0.00852	CcSEcCtD
Podofilox—Dermatitis bullous—Gemcitabine—urinary bladder cancer	0.000175	0.00843	CcSEcCtD
Podofilox—NR3C1—vagina—urinary bladder cancer	0.000175	0.0107	CbGeAlD
Podofilox—Dermatitis bullous—Fluorouracil—urinary bladder cancer	0.000172	0.00829	CcSEcCtD
Podofilox—Pain—Mitomycin—urinary bladder cancer	0.000166	0.00801	CcSEcCtD
Podofilox—Redness—Epirubicin—urinary bladder cancer	0.000163	0.00787	CcSEcCtD
Podofilox—Swelling—Etoposide—urinary bladder cancer	0.000162	0.0078	CcSEcCtD
Podofilox—TUBB—Azacitidine—Gemcitabine—urinary bladder cancer	0.000158	0.123	CbGdCrCtD
Podofilox—TOP2A—Doxorubicin—Valrubicin—urinary bladder cancer	0.000153	0.12	CbGdCrCtD
Podofilox—TOP2A—Idarubicin—Valrubicin—urinary bladder cancer	0.000153	0.12	CbGdCrCtD
Podofilox—TOP2A—Epirubicin—Valrubicin—urinary bladder cancer	0.000153	0.12	CbGdCrCtD
Podofilox—TOP2A—Daunorubicin—Valrubicin—urinary bladder cancer	0.000153	0.12	CbGdCrCtD
Podofilox—Blister—Epirubicin—urinary bladder cancer	0.000153	0.00738	CcSEcCtD
Podofilox—Skin ulcer—Methotrexate—urinary bladder cancer	0.000151	0.0073	CcSEcCtD
Podofilox—Redness—Doxorubicin—urinary bladder cancer	0.000151	0.00729	CcSEcCtD
Podofilox—Dry skin—Fluorouracil—urinary bladder cancer	0.00015	0.00727	CcSEcCtD
Podofilox—CYP3A4—female reproductive system—urinary bladder cancer	0.000146	0.00891	CbGeAlD
Podofilox—Haematuria—Thiotepa—urinary bladder cancer	0.000146	0.00704	CcSEcCtD
Podofilox—Skin ulcer—Epirubicin—urinary bladder cancer	0.000141	0.00683	CcSEcCtD
Podofilox—Blister—Doxorubicin—urinary bladder cancer	0.000141	0.00682	CcSEcCtD
Podofilox—Haemoglobin—Thiotepa—urinary bladder cancer	0.000138	0.00666	CcSEcCtD
Podofilox—Haemorrhage—Thiotepa—urinary bladder cancer	0.000137	0.00663	CcSEcCtD
Podofilox—Stinging—Epirubicin—urinary bladder cancer	0.000136	0.00656	CcSEcCtD
Podofilox—Skin ulcer—Doxorubicin—urinary bladder cancer	0.000131	0.00632	CcSEcCtD
Podofilox—Skin discolouration—Methotrexate—urinary bladder cancer	0.00013	0.00629	CcSEcCtD
Podofilox—Dizziness—Mitomycin—urinary bladder cancer	0.000128	0.00619	CcSEcCtD
Podofilox—Stinging—Doxorubicin—urinary bladder cancer	0.000126	0.00607	CcSEcCtD
Podofilox—Ulcer—Methotrexate—urinary bladder cancer	0.000124	0.00601	CcSEcCtD
Podofilox—Immune system disorder—Thiotepa—urinary bladder cancer	0.000124	0.00599	CcSEcCtD
Podofilox—Vomiting—Mitomycin—urinary bladder cancer	0.000123	0.00596	CcSEcCtD
Podofilox—Haematuria—Gemcitabine—urinary bladder cancer	0.000123	0.00592	CcSEcCtD
Podofilox—Rash—Mitomycin—urinary bladder cancer	0.000122	0.00591	CcSEcCtD
Podofilox—Dermatitis—Mitomycin—urinary bladder cancer	0.000122	0.0059	CcSEcCtD
Podofilox—Skin discolouration—Epirubicin—urinary bladder cancer	0.000122	0.00589	CcSEcCtD
Podofilox—Headache—Mitomycin—urinary bladder cancer	0.000122	0.00587	CcSEcCtD
Podofilox—Inflammation—Methotrexate—urinary bladder cancer	0.000121	0.00586	CcSEcCtD
Podofilox—Erythema—Thiotepa—urinary bladder cancer	0.00012	0.00577	CcSEcCtD
Podofilox—Ulcer—Epirubicin—urinary bladder cancer	0.000116	0.00562	CcSEcCtD
Podofilox—Haemoglobin—Gemcitabine—urinary bladder cancer	0.000116	0.00561	CcSEcCtD
Podofilox—Haemorrhage—Gemcitabine—urinary bladder cancer	0.000116	0.00558	CcSEcCtD
Podofilox—Haemoglobin—Fluorouracil—urinary bladder cancer	0.000114	0.00551	CcSEcCtD
Podofilox—Haemorrhage—Fluorouracil—urinary bladder cancer	0.000114	0.00548	CcSEcCtD
Podofilox—Inflammation—Epirubicin—urinary bladder cancer	0.000114	0.00548	CcSEcCtD
Podofilox—NR3C1—lymph node—urinary bladder cancer	0.000113	0.00689	CbGeAlD
Podofilox—Skin discolouration—Doxorubicin—urinary bladder cancer	0.000113	0.00545	CcSEcCtD
Podofilox—Skin exfoliation—Methotrexate—urinary bladder cancer	0.000112	0.00542	CcSEcCtD
Podofilox—Ulcer—Doxorubicin—urinary bladder cancer	0.000108	0.0052	CcSEcCtD
Podofilox—Skin exfoliation—Epirubicin—urinary bladder cancer	0.000105	0.00508	CcSEcCtD
Podofilox—Inflammation—Doxorubicin—urinary bladder cancer	0.000105	0.00507	CcSEcCtD
Podofilox—Immune system disorder—Gemcitabine—urinary bladder cancer	0.000104	0.00504	CcSEcCtD
Podofilox—TOP2A—Teniposide—Etoposide—urinary bladder cancer	0.000102	0.0799	CbGdCrCtD
Podofilox—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000101	0.00488	CcSEcCtD
Podofilox—Erythema—Gemcitabine—urinary bladder cancer	0.000101	0.00485	CcSEcCtD
Podofilox—Erythema—Fluorouracil—urinary bladder cancer	9.89e-05	0.00477	CcSEcCtD
Podofilox—Skin exfoliation—Doxorubicin—urinary bladder cancer	9.73e-05	0.0047	CcSEcCtD
Podofilox—Immune system disorder—Cisplatin—urinary bladder cancer	9.73e-05	0.0047	CcSEcCtD
Podofilox—Skin disorder—Thiotepa—urinary bladder cancer	9.48e-05	0.00458	CcSEcCtD
Podofilox—Erythema—Cisplatin—urinary bladder cancer	9.37e-05	0.00453	CcSEcCtD
Podofilox—Immune system disorder—Etoposide—urinary bladder cancer	8.91e-05	0.0043	CcSEcCtD
Podofilox—Paraesthesia—Thiotepa—urinary bladder cancer	8.76e-05	0.00423	CcSEcCtD
Podofilox—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	8.5e-05	0.0041	CcSEcCtD
Podofilox—Dermatitis bullous—Epirubicin—urinary bladder cancer	8.36e-05	0.00404	CcSEcCtD
Podofilox—Pain—Thiotepa—urinary bladder cancer	8.34e-05	0.00403	CcSEcCtD
Podofilox—Oedema—Gemcitabine—urinary bladder cancer	8.21e-05	0.00396	CcSEcCtD
Podofilox—Oedema—Fluorouracil—urinary bladder cancer	8.07e-05	0.0039	CcSEcCtD
Podofilox—Skin disorder—Gemcitabine—urinary bladder cancer	7.97e-05	0.00385	CcSEcCtD
Podofilox—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	7.93e-05	0.00383	CcSEcCtD
Podofilox—Dermatitis bullous—Doxorubicin—urinary bladder cancer	7.74e-05	0.00374	CcSEcCtD
Podofilox—Oedema—Cisplatin—urinary bladder cancer	7.65e-05	0.00369	CcSEcCtD
Podofilox—Skin disorder—Cisplatin—urinary bladder cancer	7.43e-05	0.00359	CcSEcCtD
Podofilox—Insomnia—Gemcitabine—urinary bladder cancer	7.42e-05	0.00358	CcSEcCtD
Podofilox—Paraesthesia—Gemcitabine—urinary bladder cancer	7.37e-05	0.00356	CcSEcCtD
Podofilox—Dry skin—Epirubicin—urinary bladder cancer	7.33e-05	0.00354	CcSEcCtD
Podofilox—Insomnia—Fluorouracil—urinary bladder cancer	7.3e-05	0.00352	CcSEcCtD
Podofilox—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	7.26e-05	0.00351	CcSEcCtD
Podofilox—Paraesthesia—Fluorouracil—urinary bladder cancer	7.25e-05	0.0035	CcSEcCtD
Podofilox—Pain—Gemcitabine—urinary bladder cancer	7.02e-05	0.00339	CcSEcCtD
Podofilox—Pruritus—Thiotepa—urinary bladder cancer	6.9e-05	0.00333	CcSEcCtD
Podofilox—Pain—Fluorouracil—urinary bladder cancer	6.9e-05	0.00333	CcSEcCtD
Podofilox—Paraesthesia—Cisplatin—urinary bladder cancer	6.87e-05	0.00332	CcSEcCtD
Podofilox—Skin disorder—Etoposide—urinary bladder cancer	6.81e-05	0.00329	CcSEcCtD
Podofilox—Dry skin—Doxorubicin—urinary bladder cancer	6.78e-05	0.00327	CcSEcCtD
Podofilox—Pain—Cisplatin—urinary bladder cancer	6.54e-05	0.00316	CcSEcCtD
Podofilox—Dizziness—Thiotepa—urinary bladder cancer	6.45e-05	0.00311	CcSEcCtD
Podofilox—Paraesthesia—Etoposide—urinary bladder cancer	6.29e-05	0.00304	CcSEcCtD
Podofilox—Haematuria—Methotrexate—urinary bladder cancer	6.28e-05	0.00303	CcSEcCtD
Podofilox—Vomiting—Thiotepa—urinary bladder cancer	6.2e-05	0.00299	CcSEcCtD
Podofilox—Rash—Thiotepa—urinary bladder cancer	6.15e-05	0.00297	CcSEcCtD
Podofilox—Dermatitis—Thiotepa—urinary bladder cancer	6.15e-05	0.00297	CcSEcCtD
Podofilox—Headache—Thiotepa—urinary bladder cancer	6.11e-05	0.00295	CcSEcCtD
Podofilox—Pain—Etoposide—urinary bladder cancer	5.99e-05	0.00289	CcSEcCtD
Podofilox—Haemoglobin—Methotrexate—urinary bladder cancer	5.94e-05	0.00287	CcSEcCtD
Podofilox—Haemorrhage—Methotrexate—urinary bladder cancer	5.91e-05	0.00285	CcSEcCtD
Podofilox—Haematuria—Epirubicin—urinary bladder cancer	5.87e-05	0.00284	CcSEcCtD
Podofilox—Pruritus—Gemcitabine—urinary bladder cancer	5.81e-05	0.0028	CcSEcCtD
Podofilox—TOP2A—Cytarabine—Gemcitabine—urinary bladder cancer	5.76e-05	0.0449	CbGdCrCtD
Podofilox—Pruritus—Fluorouracil—urinary bladder cancer	5.71e-05	0.00276	CcSEcCtD
Podofilox—Haemoglobin—Epirubicin—urinary bladder cancer	5.56e-05	0.00268	CcSEcCtD
Podofilox—Haemorrhage—Epirubicin—urinary bladder cancer	5.53e-05	0.00267	CcSEcCtD
Podofilox—Haematuria—Doxorubicin—urinary bladder cancer	5.43e-05	0.00262	CcSEcCtD
Podofilox—TOP2A—Doxorubicin—Epirubicin—urinary bladder cancer	5.34e-05	0.0417	CbGdCrCtD
Podofilox—TOP2A—Daunorubicin—Epirubicin—urinary bladder cancer	5.34e-05	0.0417	CbGdCrCtD
Podofilox—TOP2A—Idarubicin—Epirubicin—urinary bladder cancer	5.34e-05	0.0417	CbGdCrCtD
Podofilox—Immune system disorder—Methotrexate—urinary bladder cancer	5.34e-05	0.00258	CcSEcCtD
Podofilox—Dizziness—Fluorouracil—urinary bladder cancer	5.34e-05	0.00258	CcSEcCtD
Podofilox—Vomiting—Gemcitabine—urinary bladder cancer	5.22e-05	0.00252	CcSEcCtD
Podofilox—Rash—Gemcitabine—urinary bladder cancer	5.18e-05	0.0025	CcSEcCtD
Podofilox—Dermatitis—Gemcitabine—urinary bladder cancer	5.17e-05	0.0025	CcSEcCtD
Podofilox—Erythema—Methotrexate—urinary bladder cancer	5.14e-05	0.00248	CcSEcCtD
Podofilox—Haemoglobin—Doxorubicin—urinary bladder cancer	5.14e-05	0.00248	CcSEcCtD
Podofilox—Headache—Gemcitabine—urinary bladder cancer	5.14e-05	0.00248	CcSEcCtD
Podofilox—Vomiting—Fluorouracil—urinary bladder cancer	5.13e-05	0.00248	CcSEcCtD
Podofilox—Haemorrhage—Doxorubicin—urinary bladder cancer	5.12e-05	0.00247	CcSEcCtD
Podofilox—Rash—Fluorouracil—urinary bladder cancer	5.09e-05	0.00246	CcSEcCtD
Podofilox—Dermatitis—Fluorouracil—urinary bladder cancer	5.08e-05	0.00245	CcSEcCtD
Podofilox—Headache—Fluorouracil—urinary bladder cancer	5.06e-05	0.00244	CcSEcCtD
Podofilox—Immune system disorder—Epirubicin—urinary bladder cancer	4.99e-05	0.00241	CcSEcCtD
Podofilox—Pruritus—Etoposide—urinary bladder cancer	4.96e-05	0.00239	CcSEcCtD
Podofilox—TOP2A—Daunorubicin—Doxorubicin—urinary bladder cancer	4.94e-05	0.0386	CbGdCrCtD
Podofilox—TOP2A—Idarubicin—Doxorubicin—urinary bladder cancer	4.94e-05	0.0386	CbGdCrCtD
Podofilox—TOP2A—Epirubicin—Doxorubicin—urinary bladder cancer	4.94e-05	0.0386	CbGdCrCtD
Podofilox—Vomiting—Cisplatin—urinary bladder cancer	4.86e-05	0.00235	CcSEcCtD
Podofilox—Rash—Cisplatin—urinary bladder cancer	4.82e-05	0.00233	CcSEcCtD
Podofilox—Dermatitis—Cisplatin—urinary bladder cancer	4.82e-05	0.00233	CcSEcCtD
Podofilox—Erythema—Epirubicin—urinary bladder cancer	4.81e-05	0.00232	CcSEcCtD
Podofilox—Dizziness—Etoposide—urinary bladder cancer	4.63e-05	0.00224	CcSEcCtD
Podofilox—Immune system disorder—Doxorubicin—urinary bladder cancer	4.62e-05	0.00223	CcSEcCtD
Podofilox—Vomiting—Etoposide—urinary bladder cancer	4.46e-05	0.00215	CcSEcCtD
Podofilox—Erythema—Doxorubicin—urinary bladder cancer	4.45e-05	0.00215	CcSEcCtD
Podofilox—Rash—Etoposide—urinary bladder cancer	4.42e-05	0.00213	CcSEcCtD
Podofilox—Dermatitis—Etoposide—urinary bladder cancer	4.41e-05	0.00213	CcSEcCtD
Podofilox—Headache—Etoposide—urinary bladder cancer	4.39e-05	0.00212	CcSEcCtD
Podofilox—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	4.35e-05	0.0021	CcSEcCtD
Podofilox—TOP2A—Azacitidine—Gemcitabine—urinary bladder cancer	4.13e-05	0.0322	CbGdCrCtD
Podofilox—Skin disorder—Methotrexate—urinary bladder cancer	4.08e-05	0.00197	CcSEcCtD
Podofilox—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	4.07e-05	0.00196	CcSEcCtD
Podofilox—Oedema—Epirubicin—urinary bladder cancer	3.93e-05	0.0019	CcSEcCtD
Podofilox—TOP2A—Cell Cycle—LIG1—urinary bladder cancer	3.89e-05	0.00244	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—STAG2—urinary bladder cancer	3.89e-05	0.00244	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—IFNA2—urinary bladder cancer	3.84e-05	0.00241	CbGpPWpGaD
Podofilox—TOP2A—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	3.83e-05	0.00241	CbGpPWpGaD
Podofilox—Skin disorder—Epirubicin—urinary bladder cancer	3.82e-05	0.00184	CcSEcCtD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	3.8e-05	0.00238	CbGpPWpGaD
Podofilox—Insomnia—Methotrexate—urinary bladder cancer	3.8e-05	0.00183	CcSEcCtD
Podofilox—Paraesthesia—Methotrexate—urinary bladder cancer	3.77e-05	0.00182	CcSEcCtD
Podofilox—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	3.77e-05	0.00182	CcSEcCtD
Podofilox—TOP2A—Circadian rythm related genes—FAS—urinary bladder cancer	3.65e-05	0.00229	CbGpPWpGaD
Podofilox—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	3.64e-05	0.00229	CbGpPWpGaD
Podofilox—Oedema—Doxorubicin—urinary bladder cancer	3.64e-05	0.00175	CcSEcCtD
Podofilox—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	3.59e-05	0.00226	CbGpPWpGaD
Podofilox—Pain—Methotrexate—urinary bladder cancer	3.59e-05	0.00173	CcSEcCtD
Podofilox—TOP2A—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	3.58e-05	0.00225	CbGpPWpGaD
Podofilox—Insomnia—Epirubicin—urinary bladder cancer	3.55e-05	0.00172	CcSEcCtD
Podofilox—TUBA4A—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	3.55e-05	0.00223	CbGpPWpGaD
Podofilox—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—urinary bladder cancer	3.55e-05	0.00223	CbGpPWpGaD
Podofilox—NR3C1—Adipogenesis—NCOR1—urinary bladder cancer	3.53e-05	0.00222	CbGpPWpGaD
Podofilox—Skin disorder—Doxorubicin—urinary bladder cancer	3.53e-05	0.0017	CcSEcCtD
Podofilox—Paraesthesia—Epirubicin—urinary bladder cancer	3.53e-05	0.0017	CcSEcCtD
Podofilox—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—urinary bladder cancer	3.52e-05	0.00221	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—CDKN2A—urinary bladder cancer	3.49e-05	0.00219	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	3.49e-05	0.00219	CbGpPWpGaD
Podofilox—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	3.45e-05	0.00217	CbGpPWpGaD
Podofilox—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	3.45e-05	0.00217	CbGpPWpGaD
Podofilox—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	3.41e-05	0.00214	CbGpPWpGaD
Podofilox—NR3C1—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	3.39e-05	0.00213	CbGpPWpGaD
Podofilox—TOP2A—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	3.37e-05	0.00212	CbGpPWpGaD
Podofilox—Pain—Epirubicin—urinary bladder cancer	3.36e-05	0.00162	CcSEcCtD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	3.36e-05	0.00211	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	3.34e-05	0.0021	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	3.33e-05	0.00209	CbGpPWpGaD
Podofilox—TUBA4A—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	3.31e-05	0.00208	CbGpPWpGaD
Podofilox—NR3C1—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	3.3e-05	0.00207	CbGpPWpGaD
Podofilox—NR3C1—Circadian Clock—EP300—urinary bladder cancer	3.3e-05	0.00207	CbGpPWpGaD
Podofilox—Insomnia—Doxorubicin—urinary bladder cancer	3.29e-05	0.00159	CcSEcCtD
Podofilox—Paraesthesia—Doxorubicin—urinary bladder cancer	3.26e-05	0.00158	CcSEcCtD
Podofilox—TOP2A—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	3.25e-05	0.00204	CbGpPWpGaD
Podofilox—TOP2A—Circadian rythm related genes—CDK4—urinary bladder cancer	3.21e-05	0.00201	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—RRM2—urinary bladder cancer	3.2e-05	0.00201	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—CCNE1—urinary bladder cancer	3.18e-05	0.00199	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—CXCL8—urinary bladder cancer	3.17e-05	0.00199	CbGpPWpGaD
Podofilox—NR3C1—Adipogenesis—FAS—urinary bladder cancer	3.17e-05	0.00199	CbGpPWpGaD
Podofilox—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	3.16e-05	0.00198	CbGpPWpGaD
Podofilox—CYP2C19—Biological oxidations—NAT2—urinary bladder cancer	3.15e-05	0.00198	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—TYMS—urinary bladder cancer	3.12e-05	0.00196	CbGpPWpGaD
Podofilox—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	3.11e-05	0.00196	CbGpPWpGaD
Podofilox—Pain—Doxorubicin—urinary bladder cancer	3.11e-05	0.0015	CcSEcCtD
Podofilox—CYP2C19—Metapathway biotransformation—NAT2—urinary bladder cancer	3.1e-05	0.00195	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	3.05e-05	0.00191	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—IL2—urinary bladder cancer	3.03e-05	0.0019	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	3.02e-05	0.0019	CbGpPWpGaD
Podofilox—Pruritus—Methotrexate—urinary bladder cancer	2.97e-05	0.00143	CcSEcCtD
Podofilox—TUBB—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	2.97e-05	0.00186	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—CCND1—urinary bladder cancer	2.95e-05	0.00185	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.92e-05	0.00183	CbGpPWpGaD
Podofilox—TOP2A—Circadian rythm related genes—PPARG—urinary bladder cancer	2.91e-05	0.00183	CbGpPWpGaD
Podofilox—TUBA4A—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	2.89e-05	0.00181	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.88e-05	0.00181	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—MMP9—urinary bladder cancer	2.87e-05	0.0018	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—PTEN—urinary bladder cancer	2.85e-05	0.00179	CbGpPWpGaD
Podofilox—TOP2A—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	2.85e-05	0.00179	CbGpPWpGaD
Podofilox—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	2.84e-05	0.00179	CbGpPWpGaD
Podofilox—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	2.8e-05	0.00176	CbGpPWpGaD
Podofilox—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—urinary bladder cancer	2.79e-05	0.00175	CbGpPWpGaD
Podofilox—Pruritus—Epirubicin—urinary bladder cancer	2.78e-05	0.00134	CcSEcCtD
Podofilox—Dizziness—Methotrexate—urinary bladder cancer	2.78e-05	0.00134	CcSEcCtD
Podofilox—TOP2A—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	2.76e-05	0.00173	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—PLAU—urinary bladder cancer	2.73e-05	0.00171	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—SMC1A—urinary bladder cancer	2.72e-05	0.00171	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	2.72e-05	0.00171	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—EP300—urinary bladder cancer	2.72e-05	0.00171	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—TERT—urinary bladder cancer	2.72e-05	0.00171	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—CCNE1—urinary bladder cancer	2.7e-05	0.0017	CbGpPWpGaD
Podofilox—Vomiting—Methotrexate—urinary bladder cancer	2.67e-05	0.00129	CcSEcCtD
Podofilox—NR3C1—Glucocorticoid receptor regulatory network—IL2—urinary bladder cancer	2.67e-05	0.00168	CbGpPWpGaD
Podofilox—TOP2A—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	2.67e-05	0.00167	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—TYMS—urinary bladder cancer	2.65e-05	0.00167	CbGpPWpGaD
Podofilox—Rash—Methotrexate—urinary bladder cancer	2.65e-05	0.00128	CcSEcCtD
Podofilox—Dermatitis—Methotrexate—urinary bladder cancer	2.64e-05	0.00128	CcSEcCtD
Podofilox—Headache—Methotrexate—urinary bladder cancer	2.63e-05	0.00127	CcSEcCtD
Podofilox—Dizziness—Epirubicin—urinary bladder cancer	2.6e-05	0.00125	CcSEcCtD
Podofilox—Pruritus—Doxorubicin—urinary bladder cancer	2.57e-05	0.00124	CcSEcCtD
Podofilox—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	2.54e-05	0.0016	CbGpPWpGaD
Podofilox—NR3C1—Adipogenesis—PPARG—urinary bladder cancer	2.53e-05	0.00159	CbGpPWpGaD
Podofilox—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—urinary bladder cancer	2.52e-05	0.00158	CbGpPWpGaD
Podofilox—CYP2C19—Biological oxidations—HPGDS—urinary bladder cancer	2.52e-05	0.00158	CbGpPWpGaD
Podofilox—Vomiting—Epirubicin—urinary bladder cancer	2.5e-05	0.00121	CcSEcCtD
Podofilox—Rash—Epirubicin—urinary bladder cancer	2.48e-05	0.0012	CcSEcCtD
Podofilox—Dermatitis—Epirubicin—urinary bladder cancer	2.47e-05	0.00119	CcSEcCtD
Podofilox—Headache—Epirubicin—urinary bladder cancer	2.46e-05	0.00119	CcSEcCtD
Podofilox—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	2.45e-05	0.00154	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—ATM—urinary bladder cancer	2.44e-05	0.00153	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	2.44e-05	0.00153	CbGpPWpGaD
Podofilox—CYP2C19—Biological oxidations—GSTT1—urinary bladder cancer	2.44e-05	0.00153	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—CDK4—urinary bladder cancer	2.43e-05	0.00153	CbGpPWpGaD
Podofilox—NR3C1—Adipogenesis—RB1—urinary bladder cancer	2.42e-05	0.00152	CbGpPWpGaD
Podofilox—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	2.42e-05	0.00152	CbGpPWpGaD
Podofilox—Dizziness—Doxorubicin—urinary bladder cancer	2.4e-05	0.00116	CcSEcCtD
Podofilox—NR3C1—Adipogenesis—IGF1—urinary bladder cancer	2.4e-05	0.00151	CbGpPWpGaD
Podofilox—NR3C1—Glucocorticoid receptor regulatory network—EP300—urinary bladder cancer	2.39e-05	0.0015	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	2.39e-05	0.0015	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—MYC—urinary bladder cancer	2.37e-05	0.00149	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—RB1—urinary bladder cancer	2.37e-05	0.00149	CbGpPWpGaD
Podofilox—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	2.35e-05	0.00148	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	2.31e-05	0.00145	CbGpPWpGaD
Podofilox—Vomiting—Doxorubicin—urinary bladder cancer	2.31e-05	0.00112	CcSEcCtD
Podofilox—TUBB—Cell Cycle—TERT—urinary bladder cancer	2.31e-05	0.00145	CbGpPWpGaD
Podofilox—Rash—Doxorubicin—urinary bladder cancer	2.29e-05	0.00111	CcSEcCtD
Podofilox—Dermatitis—Doxorubicin—urinary bladder cancer	2.29e-05	0.00111	CcSEcCtD
Podofilox—TOP2A—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	2.28e-05	0.00143	CbGpPWpGaD
Podofilox—Headache—Doxorubicin—urinary bladder cancer	2.28e-05	0.0011	CcSEcCtD
Podofilox—TUBA4A—Hemostasis—CREBBP—urinary bladder cancer	2.25e-05	0.00141	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—IGF1—urinary bladder cancer	2.22e-05	0.00139	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.16e-05	0.00135	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—RB1—urinary bladder cancer	2.11e-05	0.00133	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	2.11e-05	0.00133	CbGpPWpGaD
Podofilox—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	2.11e-05	0.00132	CbGpPWpGaD
Podofilox—NR3C1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	2.1e-05	0.00132	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.09e-05	0.00131	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.08e-05	0.00131	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	2.08e-05	0.00131	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—ATM—urinary bladder cancer	2.08e-05	0.0013	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	2.07e-05	0.0013	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—CDK4—urinary bladder cancer	2.07e-05	0.0013	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—RHOA—urinary bladder cancer	2.03e-05	0.00128	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle, Mitotic—RB1—urinary bladder cancer	2.01e-05	0.00126	CbGpPWpGaD
Podofilox—TOP2A—Circadian rythm related genes—PTEN—urinary bladder cancer	2e-05	0.00126	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.99e-05	0.00125	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—TP53—urinary bladder cancer	1.94e-05	0.00122	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.93e-05	0.00121	CbGpPWpGaD
Podofilox—TOP2A—Circadian rythm related genes—EP300—urinary bladder cancer	1.91e-05	0.0012	CbGpPWpGaD
Podofilox—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	1.89e-05	0.00119	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—CCNE1—urinary bladder cancer	1.89e-05	0.00119	CbGpPWpGaD
Podofilox—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	1.87e-05	0.00117	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—CDKN2A—urinary bladder cancer	1.86e-05	0.00117	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—TYMS—urinary bladder cancer	1.85e-05	0.00116	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	1.82e-05	0.00114	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—RB1—urinary bladder cancer	1.8e-05	0.00113	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	1.77e-05	0.00111	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	1.76e-05	0.0011	CbGpPWpGaD
Podofilox—TUBA4A—Metabolism of proteins—IGF1—urinary bladder cancer	1.75e-05	0.0011	CbGpPWpGaD
Podofilox—NR3C1—Adipogenesis—CDKN1A—urinary bladder cancer	1.74e-05	0.00109	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.73e-05	0.00109	CbGpPWpGaD
Podofilox—NR3C1—Glucocorticoid receptor regulatory network—TP53—urinary bladder cancer	1.71e-05	0.00108	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—IL2—urinary bladder cancer	1.71e-05	0.00107	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	1.7e-05	0.00107	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.69e-05	0.00106	CbGpPWpGaD
Podofilox—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	1.69e-05	0.00106	CbGpPWpGaD
Podofilox—NR3C1—Generic Transcription Pathway—ESR2—urinary bladder cancer	1.67e-05	0.00105	CbGpPWpGaD
Podofilox—NR3C1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	1.67e-05	0.00105	CbGpPWpGaD
Podofilox—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.67e-05	0.00105	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	1.62e-05	0.00102	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—EP300—urinary bladder cancer	1.62e-05	0.00102	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—TERT—urinary bladder cancer	1.62e-05	0.00101	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.61e-05	0.00101	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.6e-05	0.001	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—CDKN2A—urinary bladder cancer	1.58e-05	0.000993	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—CCND1—urinary bladder cancer	1.57e-05	0.000986	CbGpPWpGaD
Podofilox—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	1.55e-05	0.000976	CbGpPWpGaD
Podofilox—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.53e-05	0.000962	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—EP300—urinary bladder cancer	1.53e-05	0.000962	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—CDKN1A—urinary bladder cancer	1.52e-05	0.000954	CbGpPWpGaD
Podofilox—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	1.51e-05	0.00095	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	1.49e-05	0.000938	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—SRC—urinary bladder cancer	1.49e-05	0.000935	CbGpPWpGaD
Podofilox—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	1.47e-05	0.000921	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—ATM—urinary bladder cancer	1.45e-05	0.000912	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—CDK4—urinary bladder cancer	1.45e-05	0.000908	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—EP300—urinary bladder cancer	1.45e-05	0.000908	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	1.44e-05	0.000907	CbGpPWpGaD
Podofilox—NR3C1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	1.43e-05	0.000899	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.42e-05	0.000893	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—MYC—urinary bladder cancer	1.41e-05	0.000885	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—RB1—urinary bladder cancer	1.41e-05	0.000883	CbGpPWpGaD
Podofilox—TUBA4A—Metabolism of proteins—CXCL8—urinary bladder cancer	1.41e-05	0.000882	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle, Mitotic—EP300—urinary bladder cancer	1.37e-05	0.000863	CbGpPWpGaD
Podofilox—TOP2A—Circadian rythm related genes—TP53—urinary bladder cancer	1.36e-05	0.000857	CbGpPWpGaD
Podofilox—NR3C1—Adipogenesis—TNF—urinary bladder cancer	1.34e-05	0.000844	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—CCND1—urinary bladder cancer	1.34e-05	0.000839	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—CDKN1A—urinary bladder cancer	1.29e-05	0.000811	CbGpPWpGaD
Podofilox—NR3C1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	1.29e-05	0.00081	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—MYC—urinary bladder cancer	1.26e-05	0.000791	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—RB1—urinary bladder cancer	1.26e-05	0.00079	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	1.24e-05	0.000776	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—KRAS—urinary bladder cancer	1.23e-05	0.000775	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—EP300—urinary bladder cancer	1.23e-05	0.000772	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle, Mitotic—MYC—urinary bladder cancer	1.2e-05	0.000752	CbGpPWpGaD
Podofilox—NR3C1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	1.16e-05	0.00073	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—CDKN2A—urinary bladder cancer	1.11e-05	0.000694	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—TP53—urinary bladder cancer	1.1e-05	0.000688	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—MYC—urinary bladder cancer	1.07e-05	0.000673	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—HRAS—urinary bladder cancer	1.05e-05	0.000658	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	1.04e-05	0.000656	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	1.04e-05	0.000651	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—TP53—urinary bladder cancer	1.03e-05	0.00065	CbGpPWpGaD
Podofilox—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	1.02e-05	0.000639	CbGpPWpGaD
Podofilox—NR3C1—Generic Transcription Pathway—ESR1—urinary bladder cancer	1.01e-05	0.000636	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	1.01e-05	0.000635	CbGpPWpGaD
Podofilox—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	1e-05	0.00063	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	9.82e-06	0.000617	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—NAT1—urinary bladder cancer	9.82e-06	0.000617	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.66e-06	0.000607	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—EP300—urinary bladder cancer	9.61e-06	0.000604	CbGpPWpGaD
Podofilox—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	9.34e-06	0.000587	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—CCND1—urinary bladder cancer	9.34e-06	0.000587	CbGpPWpGaD
Podofilox—NR3C1—Generic Transcription Pathway—PPARG—urinary bladder cancer	9.24e-06	0.00058	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—SMC1A—urinary bladder cancer	9.23e-06	0.000579	CbGpPWpGaD
Podofilox—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	9.22e-06	0.000579	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—CDKN1A—urinary bladder cancer	9.03e-06	0.000567	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	8.98e-06	0.000564	CbGpPWpGaD
Podofilox—NR3C1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	8.88e-06	0.000558	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—TP53—urinary bladder cancer	8.8e-06	0.000552	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—EP300—urinary bladder cancer	8.6e-06	0.00054	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—MYC—urinary bladder cancer	8.38e-06	0.000526	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	8.09e-06	0.000508	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—ESR2—urinary bladder cancer	8.04e-06	0.000505	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	7.64e-06	0.00048	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—MYC—urinary bladder cancer	7.49e-06	0.00047	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	7.44e-06	0.000467	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	6.23e-06	0.000391	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—NCOR1—urinary bladder cancer	6.21e-06	0.00039	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—TP53—urinary bladder cancer	6.15e-06	0.000386	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.97e-06	0.000375	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—TYMP—urinary bladder cancer	5.95e-06	0.000374	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	5.91e-06	0.000371	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—NAT1—urinary bladder cancer	5.91e-06	0.000371	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—ERCC2—urinary bladder cancer	5.84e-06	0.000367	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.71e-06	0.000359	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	5.4e-06	0.000339	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—NAT2—urinary bladder cancer	5.38e-06	0.000338	CbGpPWpGaD
Podofilox—NR3C1—Generic Transcription Pathway—MYC—urinary bladder cancer	5.27e-06	0.000331	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—ESR1—urinary bladder cancer	4.88e-06	0.000306	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.86e-06	0.000305	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—RRM2—urinary bladder cancer	4.64e-06	0.000292	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	4.59e-06	0.000288	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	4.48e-06	0.000281	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—PPARG—urinary bladder cancer	4.45e-06	0.000279	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—ENO2—urinary bladder cancer	4.3e-06	0.00027	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	4.3e-06	0.00027	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.28e-06	0.000269	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	4.27e-06	0.000268	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	4.17e-06	0.000262	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.11e-06	0.000258	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.58e-06	0.000225	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—NQO1—urinary bladder cancer	3.47e-06	0.000218	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.36e-06	0.000211	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—NAT2—urinary bladder cancer	3.24e-06	0.000203	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.93e-06	0.000184	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	2.89e-06	0.000182	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.8e-06	0.000176	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.79e-06	0.000175	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.69e-06	0.000169	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.66e-06	0.000167	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.66e-06	0.000167	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.59e-06	0.000162	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.59e-06	0.000162	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.54e-06	0.00016	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—MYC—urinary bladder cancer	2.54e-06	0.000159	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.51e-06	0.000158	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.5e-06	0.000157	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	2.35e-06	0.000147	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.09e-06	0.000131	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.9e-06	0.00012	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.83e-06	0.000115	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.74e-06	0.000109	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.62e-06	0.000102	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.6e-06	0.0001	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.6e-06	0.0001	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.53e-06	9.61e-05	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.5e-06	9.44e-05	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.5e-06	9.41e-05	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.41e-06	8.87e-05	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.31e-06	8.21e-05	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.25e-06	7.83e-05	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.15e-06	7.19e-05	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.1e-06	6.91e-05	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	9.01e-07	5.66e-05	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—PTEN—urinary bladder cancer	7.86e-07	4.93e-05	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—EP300—urinary bladder cancer	7.49e-07	4.71e-05	CbGpPWpGaD
